STAAR Reports 6 Percent Increase in Net Sales in Q1-2017

May 12, 2017: By Jon Swedien

STAARSTAAR Surgical had net sales of $20.4 million in Q1-2017, a 6 percent increase over its Q1-2016 net sales, the company reported May 3.

Net sales of STAAR’s Visian Implantable Collamer Lens (ICL) were up 16 percent for Q1-2017 compared with the same quarter in 2016, according to the Monrovia, California, company.

The number of ICLs units sold was up 20 percent for Q1-2017 compared with Q1-2016.

STAAR’s sales for ICLs grew 65 percent in Canada, 65 percent in Japan, and 45 percent in China in Q1-2017 compared with Q1-2016, the company said.

The company’s IOL sales were down 9 percent in Q1-2017 compared with Q1-2016, while the number of units sold was flat. Injector parts dropped 54 percent.

STAAR said it anticipates flat to declining growth for IOL sales in 2017 with the discontinuation of its US silicone IOL business.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Quidel Acquires RPS’ InflammaDry, AdenoPlus Ophthalmic Diagnostic Tests

Gottlieb Says US FDA Can Help Reduce Drug Prices through Generics, Biosimilars

ONL Therapeutics Closes $4.25 Million Series A Financing

Omeros’ Omidria Revenues Total $12.3 Million in Q1-2017

Finland Eye Care Provider Silmäasema Oyj Plans IPO to Raise €35 Million

Alcon Introduces SYSTANE ICAPS Chewable Eye Vitamin

Aerie’s Rhopressa Gets Target Action Date from US FDA

STAAR’s EVO+ Visian ICL with Aspheric (EDOF) Optic Receives CE Mark Approval

Refocus to File for US Approval of VisAbility for Presbyopia in Q3-2017

Trial for James Mazzo Ends in Hung Jury; Co-defendants DeCinces, Parker Convicted

Alcon Names Stephen S. Lane, MD, as Chief Medical Officer

Allergan’s Restasis Sales Increase 3.4 Percent in Q1-2017

Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

LENSAR Becomes Subsidiary of PDL, Gains FDA Clearance for Laser Integration with Pentacam, Aladdin

Bausch + Lomb Posts Q1-2017 Revenues of $1.15 Billion in ‘Solid Quarter’

Carl Zeiss Meditec’s Revenues Grow 8.6 percent in First Half of Fiscal Year

Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

Shire Licenses Parion’s P-321 for Dry Eye Disease

Imprimis’ Ophthalmic Sales Grow 105 Percent in Q1-2017

Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

Coming soon

2017 Ophthalmic Laser Report: A Global Market Analysis for 2016 to 2022 (Photocoagulation, Photodisruption, and SLT)